New adjuvants in evolving vaccine strategies

Expert Opinion on Biological Therapy

Volumn 11, Issue 7, 2011, Pages 827-832

  Buonaguro, Franco M ^a   Tornesello, Maria Lina ^a   Buonaguro, Luigi ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

adjuvants; AS04; HPV vaccine; MLA

Indexed keywords

CYTOKINE; DNA VACCINE; HEPATITIS B VACCINE; HERPES VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; VACCINE;

ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMORAL IMMUNITY; MEMORY CELL; NONHUMAN; REVIEW; TH1 CELL; TH2 CELL; VACCINATION; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; B-LYMPHOCYTES; CHEMISTRY, PHARMACEUTICAL; HUMANS; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; LIPID A; PAPILLOMAVIRUS VACCINES; TH1 CELLS; TH2 CELLS;

HUMAN PAPILLOMAVIRUS;

EID: 79958228582     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.587802     Document Type: Review

References (55)

1. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82:497-505 (Pubitemid 39421059)
2. Ross AL, Brave A, Scarlatti G, et al. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis 2010;10:305-16
3. Buonaguro FM, Butler-Ransohoff JE. PharmaPlant: the new frontier in vaccines. Expert Rev Vaccines 2010;9:805-7
4. Lindblad EB, Elhay MJ, Silva R, et al. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997;65:623-9 (Pubitemid 27053234)
5. Buonaguro FM, Tomesello ML, Buonaguro L. Immune signatures and systems biology of vaccines. In: Marincola FM, Wang E, editors, In immunologic signatures of rejection. Springer Science; New York, USA; 2011. p. 141-67
6. Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 2009;8:1379-98
7. Gasparini R, Amicizia D, Manfredi P, et al. Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model. Epidemiol Infect 2009;137:794-802
8. Alphs HH, Gambhira R, Karanam B, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008;105:5850-5 (Pubitemid 351758461)
9. Alunni-Fabbroni M, Littlewood T, Deleu L, et al. Induction of S phase and apoptosis by the human papillomavirus type 16 E7 protein are separable events in immortalized rodent fibroblasts. Oncogene 2000;19:2277-85 (Pubitemid 30307203)
10. van der Burg SH. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev Vaccines 2008;7:1-5 (Pubitemid 351357961)
11. Bousarghin L, Touze A, Gaud G, et al. Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther 2009;8:357-65
12. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008;26(Suppl 10):K62-7
13. Garcon N, Chomez P, Van MM. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-39 (Pubitemid 47607848)
14. Tapping RI, Akashi S, Miyake K, et al. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000;165:5780-7
15. Baldridge JR, McGowan P, Evans JT, et al. Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-38 (Pubitemid 38937554)
16. Beran J, Hobzova L, Wertzova V, et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin 2010;6:578-84
17. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008;8:235-47 (Pubitemid 351233716)
18. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-8
19. European Medicines Agency. Fendrix: EPAR Scientific Discussion. Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Scientific- Discussion/human/000550/ WC500021700.pdf.2005
20. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008;110:S1-10
21. Garcon N, Wettendorff M, Van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011;11:667-77
22. Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008;181:17-21
23. Tritto E, Mosca F, De GE. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009;27:3331-4
24. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 1998;7:1475-82 (Pubitemid 28408808)
25. Kashala O, Amador R, Valero MV, et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 2002;20:2263-77 (Pubitemid 34497037)
26. Velez ID, Gilchrist K, Martinez S, et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009;28:329-37
27. Coler RN, Bertholet S, Moutaftsi M, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011;6:e16333
28. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009;200:337-46
29. Wobser M, Keikavoussi P, Kunzmann V, et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006;55:1294-8 (Pubitemid 43992055)
30. Saul A, Lawrence G, Allworth A, et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 2005;23:3076-83 (Pubitemid 40462448)
31. Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002;1:111-18 (Pubitemid 36686885)
32. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000;19:1180-7 (Pubitemid 32010699)
33. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009;27:4388-401
34. Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 2011;10:437-46
35. Buonaguro L, Tornesello ML, Tagliamonte M, et al. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 2006;80:9134-43 (Pubitemid 44362963)
36. Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458:1191-5
37. Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008;3:27-32 (Pubitemid 351410539)
38. Vollmer J, Weeratna R, Payette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004;34:251-62 (Pubitemid 38111541)
39. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5 (Pubitemid 32015992)
40. Bargieri DY, Rosa DS, Braga CJ, et al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 2008;26:6132-42
41. Treanor JJ, Taylor DN, Tussey L, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010;28:8268-74
42. Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 2010;185:5677-82
43. Vijay-Kumar M, Carvalho FA, Aitken JD, et al. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol 2010;40:3528-34
44. Nguyen DN, Green JJ, Chan JM, et al. Polymeric materials for gene delivery and DNA vaccination. Adv Mater 2008;20:1-21
45. Little SR, Lynn DM, Ge Q, et al. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci USA 2004;101:9534-9 (Pubitemid 38869271)
46. Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008;197:1634-42 (Pubitemid 351919626)
47. Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186-97
48. Ivory C, Chadee K. DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther 2004;2:17
49. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-92
50. Zhang Y, Taylor MG, Johansen MV, Bickle QD. Vaccination of mice with a cocktail DNA vaccine induces a Th1-type immune response and partial protection against Schistosoma japonicum infection. Vaccine 2001;20:724-30 (Pubitemid 34015811)
51. Lladser A, Mougiakakos D, Tufvesson H, et al. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther 2011;19:594-601
52. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006;8:R27
53. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802 (Pubitemid 47480309)
54. Pink JR, Kieny MP. 4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization - organisation Mondiale de la Sante Fondation Merieux, Annecy, France, 23-25, June 2003. Vaccine 2004;22:2097-102 (Pubitemid 38626045)
55. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503